ArticleBMC cancer2025
Impact of radiation dose to immune cells on survival in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a retrospective analysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.British journal of cancer · 2026Trial
- Chemotherapy and Radiotherapy Regimens for Limited-Stage Small Cell Lung Cancer Treated With Accelerated Hyperfractionated Radiotherapy Combined With Chemotherapy: A Real-World Study.Cancer medicine · 2026Article
- The Prognostic Value of EDRIC and Its Association With Radiation-Induced Lymphopenia in Patients With Esophageal Cancer Undergoing Radical Radiotherapy: A Single-Center Chinese Study.The Kaohsiung journal of medical sciences · 2026Article
- Risk stratification model based on estimated dose of radiation to immune cells and radiotherapy-related nadir lymphocyte count for predicting the efficacy of consolidation immunotherapy in stage III non-small cell lung cancer.Frontiers in immunology · 2026Article
- Impact of radiation dose to immune cells on survival in patients with extensive-stage small cell lung cancer receiving consolidative thoracic radiotherapy after chemoimmunotherapy.Future oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNeoadjuvant chemoradiotherapy (NCRT) is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). This study aims to explore the effect of the estimated dose of radiation to immune cells (EDRIC) on lymphocytes in patients with locally advanced ESCC undergoing NCRT and evaluate the impact of EDRIC on patient prognosis.
methodsThis retrospective study included patients with locally advanced ESCC who received NCRT followed by radical esophagectomy at our institution between March 2016 and December 2022. EDRIC was calculated as a function of the number of fractions and the average doses to the lungs, heart, and remaining body. The optimal cut-off value of EDRIC was determined based on disease-free survival (DFS), and patients were divided into two groups according to this cut-off value. Kaplan-Meier and Cox proportional hazards regression analyses were used to estimate overall survival (OS) and DFS.
resultsThe 182 patients included in the study had a mean EDRIC of 5.41 ± 1.70 Gy and an EDRIC cut-off value of 6.86 Gy. Patients with an EDRIC ≤ 6.86 Gy had a significant advantage in DFS (hazard ratio [HR]: 0.37, 95% confidence interval [CI]: 0.20-0.68, P = 0.001) and OS (HR: 0.22, 95% CI: 0.10-0.48, P = 0.001). EDRIC was closely associated with the lymphocyte nadir (P < 0.001) and lymphocytopenia values (P < 0.001). Patients with a lymphocyte nadir ≤ 0.16 × 10
conclusionEDRIC is an independent prognostic factor for patients with locally advanced ESCC undergoing NCRT. A higher EDRIC is associated with poorer DFS and OS and is closely related to reduced lymphocyte counts. As a quantifiable parameter, future research should explore methods of lowering EDRIC during NCRT while ensuring adequate tumor coverage and sufficient dosage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.